Ensysce Biosciences Issues Annual Shareholder Letter

PF614-301 Phase 3 Trial Enrollment Underway, Advancing Toward Market LaunchFDA Aligned with ENSC Manufacturing Path for PF614, Enabling Commercial Scale UpMPAR® Patent Protection Extended Through 2042Up to $20 Million in Funding Secured to …